Hemington Wealth Management Neurocrine Biosciences Inc Transaction History
Hemington Wealth Management
- $398 Million
- Q4 2024
A detailed history of Hemington Wealth Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Hemington Wealth Management holds 44 shares of NBIX stock, worth $5,395. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44
Previous 32
37.5%
Holding current value
$5,395
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
642Shares Held
94.3MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.74 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.23 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$631 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$316 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$229 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...